Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
NASDAQ:SYRS
Holding SYRS?
Track your performance easily
SYRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.18 - $7.96
Previous CloseN/A
Volume1.14M
Average Volume (3M)2.86M
Market Cap
$5.50M
Enterprise Value$86.52M
Total Cash (Recent Filing)$83.59M
Total Debt (Recent Filing)$53.00K
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Mar 06, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.03
Shares Outstanding26,832,457
10 Day Avg. Volume2,590,144
30 Day Avg. Volume2,860,490
Standard Deviation0.35
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.21
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap15.73
Enterprise Value/Revenue223.57
Enterprise Value/Gross Profit8.71
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$3.00Price Target Upside1263.64% Upside
Rating ConsensusHold
Number of Analyst Covering4
Syros Pharmaceuticals News
PremiumCompany Announcements
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe SELECT-MDS-1 Phase 3 trial has successfully completed enrollment for primary endpoint analysis, paving the way for potential accelerated or full approval in the US.
Market OpportunityThe large commercial opportunity for tamibarotene in RARA-positive HR-MDS is highlighted by a market opportunity valued at approximately $1.6 billion, with over $800 million attributed to RARA positive patients.
Unmet Medical NeedTamibarotene would be the first targeted therapy for the patient population, addressing the significant unmet need with approximately 50% of patients expressing RARA overexpression.
Bears Say
Analyst DowngradeSyros Pharmaceuticals has been downgraded from Buy to Neutral with a price target reduced from $6 to $1.
Clinical TrialsThe failure of SELECT-MDS-1 ends Syros' last active clinical program and triggers an event of default under the terms of the company's secured loan facility with Oxford Finance.
Stock ValuationThe stock traded down about 86% in the aftermarket, reflecting a significant decline in valuation.
---
Ownership Overview
10.40% Insiders
4.59% Mutual Funds
0.02% Other Institutional Investors
81.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was $0.18 and its highest was $7.96 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Syros Pharmaceuticals’s market cap is $5.50M.
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 47 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.676 by $0.516.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -0.72.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.676. Following the earnings report the stock price went up 0.398%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Currently, no hedge funds are holding shares in SYRS
---
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
---
SYRS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call conveyed a cautiously optimistic outlook, emphasizing the advancement of tamibarotene and its significant market potential, alongside improved financial metrics. However, the lack of revenue and decreased cash reserves present notable concerns.Read More>---
SYRS Stock 12 Month Forecast
Average Price Target
$3.00
▲(1263.64% Upside)
Technical Analysis
Mersana Therapeutics
―
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Rigel
―
Best Analysts Covering SYRS
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-55.43%
reiterated a buy rating 3 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -55.43% per trade.
---